PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Journal of Health Informatics and Statistics10.21032/jhis.2022.47.s3.s41202247Suppl 3S41-S50Adverse Drug Reaction Analysis Methods and Research Trends by Data Sources for Post-marketing SurveillanceHyunah Shin, Seonghyeon Park, Suehyun Leehttp://e-jhis.org/upload/pdf/jhis-2022-47-S3-S41.pdf, http://e-jhis.org/journal/view.php?doi=10.21032/jhis.2022.47.S3.S41, http://e-jhis.org/upload/pdf/jhis-2022-47-S3-S41.pdf
Drug Information Journal10.1177/0092861586020002041986202135-145FDA's Adverse Drug Reaction Drug Dictionary and its Role in Post-Marketing SurveillanceMary B. Forbes, Anastasia E. Perez, Alan Gelberghttp://journals.sagepub.com/doi/pdf/10.1177/009286158602000204, http://journals.sagepub.com/doi/pdf/10.1177/009286158602000204
InPharma10.1007/bf03289402197711014-5POST-MARKETING SURVEILLANCE OF ADVERSE DRUG REACTIONShttp://link.springer.com/content/pdf/10.1007/BF03289402.pdf, http://link.springer.com/article/10.1007/BF03289402/fulltext.html, http://link.springer.com/content/pdf/10.1007/BF03289402
Controlled Clinical Trials10.1016/0197-2456(91)90178-o1991125659Alert systems for post-marketing surveillance of adverse drug events— Methods and problemsM. Praus, F. Schindel, R. Fescharek, S. Schwarzhttps://api.elsevier.com/content/article/PII:019724569190178O?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:019724569190178O?httpAccept=text/plain
Drug Discovery Today10.1016/j.drudis.2008.12.0122009147-8343-357Decision support methods for the detection of adverse events in post-marketing dataM. Hauben, A. Batehttps://api.elsevier.com/content/article/PII:S135964460900004X?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S135964460900004X?httpAccept=text/plain
Trends in Pharmacological Sciences10.1016/0165-6147(86)90391-319867377-380Medical databases in post-marketing drug surveillanceBrian L. Stromhttps://api.elsevier.com/content/article/PII:0165614786903913?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:0165614786903913?httpAccept=text/plain
Pharmacological Research10.1016/s1043-6618(09)80179-5199022134Post-marketing drug surveillance and C.I.I.F.T.: Experiences concerning organization and data processG. Costa, P. Princihttps://api.elsevier.com/content/article/PII:S1043661809801795?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1043661809801795?httpAccept=text/plain
Pharmacoepidemiology and Drug Safety10.1002/pds.34122013225488-495Near real-time adverse drug reaction surveillance within population-based health networks: methodology considerations for data accrualTaliser R. Avery, Martin Kulldorff, Yury Vilk, Lingling Li, T. Craig Cheetham, Sascha Dublin, Robert L. Davis, Liyan Liu, Lisa Herrinton, Jeffrey S. Brownhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fpds.3412, https://onlinelibrary.wiley.com/doi/full/10.1002/pds.3412
Drug Safety10.1007/s40264-015-0343-3201538121211-1218Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): A National Analysis of Data from 10-Year Post-marketing SurveillanceFrancesca Renda, Giovanni Landoni, Renato Bertini Malgarini, Alessandro Assisi, Maria Luisa Azzolini, Marta Mucchetti, Giuseppe Pimpinella, Luca Panihttps://link.springer.com/content/pdf/10.1007/s40264-015-0343-3.pdf, https://link.springer.com/article/10.1007/s40264-015-0343-3/fulltext.html, http://link.springer.com/content/pdf/10.1007/s40264-015-0343-3, https://link.springer.com/content/pdf/10.1007/s40264-015-0343-3.pdf
Pharmacological Research10.1016/s1043-6618(09)80183-7199022138The physician attitude to notice the adverse drug reactions during post-marketing surveillance assessed by a simulated clinical caseC. Crotta, C. Della Pepa, M.P. Rubinetto, M. Eandihttps://api.elsevier.com/content/article/PII:S1043661809801837?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1043661809801837?httpAccept=text/plain